摘要
利拉鲁肽是一种长效人胰升糖素样肽-1（GLP-1）的类似物，可通过提供药理学浓度的GLP-1与广泛分布于全身的GLP-1受体结合，发挥葡萄糖依赖性降糖作用、胰岛细胞功能保护作用、并具有抑制胃排空、降低食触增加饱腹感、减轻体重、保护心脏、降低血压等多种2型糖尿病治疗作用。但临床应用中发现，利拉鲁肽在良好发挥降糖减重等作用的同时，常常伴发一定的胃肠道不良反应。本文通过阐述GLP-1对胃肠道作用的可能机制、利拉鲁肽临床应用经验和有效应对方法等，以期帮助临床医师更全面了解上述问题，在实践中正确使用利拉鲁肽，并尽可能减少或避免相关不良反应。
Liraglutide is a long-acting human GLP-1 analogue, which provides pharmacological level of GLP-1 and combines with GLP-1 receptor widely distributing in the body. Liraglutide demonstrates multiple antidiabetic and other effects, including glucose-dependent glucose-lowering action, pancreatic islet cells protection, gastric emptying inhibition, appetite reduction/feelings of satiety and fullness increasing, weight loss, cardioprotection and blood pressure lowering action. Meanwhile, clinical practice also shows that some gastrointestinal adverse events occur accompanying with good glucose control and weight loss. This review will explain the potential mechanisms of GLP-1 and gastrointestinal reaction, clinical evidence of liraglutide and effective management rules, aim to help readers better understand this issue, as well as to advise clinicians of proper use of liraglutide while reducing or avoiding those adverse events.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2012年第11期I0002-I0005,共4页
Chinese Journal of Endocrinology and Metabolism
